Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.6 USD | +0.19% | -0.59% | +4.27% |
May. 13 | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
May. 09 | Medincell: share price rises on resumption of trading | CF |
ETFs positioned on AbbVie Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.54% | 12 M€ | +15.09% | - | |
1.45% | 104 M€ | +9.47% | ||
1.39% | 2 M€ | +21.73% | - | |
1.35% | 1,448 M€ | -.--% | - | |
1.35% | 219 M€ | +17.17% | - | |
1.34% | 330 M€ | -.--% | ||
1.30% | 110 M€ | +9.06% | - | |
1.30% | 800 M€ | +5.82% | ||
1.24% | 85 M€ | +11.59% | - | |
1.18% | 655 M€ | -.--% | - | |
1.18% | 273 M€ | -.--% | ||
1.18% | 1,174 M€ | +23.54% | ||
1.16% | 24 M€ | +0.14% | - | |
1.16% | 224 M€ | +3.83% | - | |
1.16% | 26 M€ | +0.30% | - | |
1.06% | 375 M€ | +8.28% | ||
1.02% | 26 M€ | +20.75% | - | |
1.00% | 276 M€ | +11.40% | - | |
0.96% | 1 M€ | +0.04% | ||
0.94% | 1,848 M€ | +18.39% | - | |
0.94% | 559 M€ | +14.30% | ||
0.91% | 204 M€ | +10.54% | ||
0.90% | 6 M€ | +17.98% | - | |
0.89% | 121 M€ | +7.29% | - | |
0.87% | 1,487 M€ | +7.21% | - | |
0.81% | 8 M€ | +5.15% | - | |
0.81% | 744 M€ | +8.55% | ||
0.78% | 265 M€ | +5.42% | - | |
0.74% | 50 M€ | +9.54% | ||
0.73% | 205 M€ | -.--% | ||
0.72% | 9 M€ | +9.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 285B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B | |
-1.42% | 161B |
- Stock Market
- Equities
- ABBV Stock
- Funds and ETFs AbbVie Inc.